



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	367190	Caruso's Prostate Eze Max
<b>ARTG entry for</b>	Medicine Assessed Listed	
<b>Sponsor</b>	Caruso's Natural Health Pty Ltd	
<b>Postal Address</b>	PO Box 310, HORSLEY PARK, NSW, 2175 Australia	
<b>ARTG Start Date</b>	26/05/2021	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Conditions applicable as specified in the document "Conditions - standard and specific: Applying to registered or listed therapeutic goods under section 28 of the Therapeutic Goods Act 1989".

### Products

#### 1 . Caruso's Prostate Eze Max

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	26/05/2021
---------------------	-------------------------	-----------------------	------------

#### Permitted Indications

No Permitted Indications included on Record

#### Indication Requirements

No Indication Requirements included on Record

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

For the relief of nocturia (night-time urinary frequency) associated with medically diagnosed benign prostatic hypertrophy.

#### Warnings

No Warnings included on Record

#### Additional Product information

#### Pack Size/Poison information

<b>Pack Size</b>	<b>Poison Schedule</b>
------------------	------------------------

#### Components

##### 1 . Formulation 1

<b>Dosage Form</b>	Capsule, soft
--------------------	---------------

<b>Route of Administration</b>	Oral
--------------------------------	------

#### Visual Identification

#### Active Ingredients

<b>Cucurbita pepo seed Oil fixed</b>	<b>160 mg</b>
<b>Epilobium parviflorum herb Extract dry concentrate</b>	<b>125 mg</b>
Equivalent: Epilobium parviflorum (Dry)	500 mg
<b>lycopene</b>	<b>2.1 mg</b>



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

<b>Prunus africana stem bark outer Extract soft concentrate</b>	<b>75 mg</b>
Equivalent: Prunus africana (Dry)	15 g
<b>Serenoa repens seed Extract soft concentrate</b>	<b>44 mg</b>
Equivalent: Serenoa repens (Dry)	660 mg

**Other Ingredients (Excipients)**

allura red AC  
ascorbic acid  
colloidal anhydrous silica  
d-alpha-tocopherol  
Gelatin  
glycerol  
hydrogenated vegetable oil  
lecithin  
Maize Oil  
patent blue V  
purified water  
Soya Oil  
titanium dioxide  
yellow beeswax

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary